Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Cardiology · BMJ · 2026-11-12

In 12,434 adults with type 2 diabetes, targeting systolic BP below 120 instead of 140 mm Hg did not reduce dementia or mild cognitive impairment over about 4 years (HR 0.96). An MRI substudy showed slower growth of white matter lesions.

Secondary analysisn = 12,434
Wang et al. Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial
Cardiology · Lancet · 2026-10-29

In 5 trials (110,933 presentations) of suspected heart attack, the 0/1 h troponin pathway did not clearly differ from 0/3 h on 30-day death or new type 1 MI (0.8% vs 1.0%), and did not shorten emergency department stay.

Meta-analysisn = 110,933 presentations
Boeddinghaus et al. Performance of 0/1 h versus 0/3 h pathways in patients with suspected myocardial infarction: a systematic review and individual participant data meta-analysis of randomised controlled trials
Cardiology · JAMA Cardiol · 2026-10-01

Post hoc analysis of HELIOS-B (548 patients with ATTR cardiomyopathy): right ventricular free wall strain was abnormal in 85% and independently predicted death and cardiovascular events. Vutrisiran stabilised it over 30 months versus placebo.

Secondary analysisn = 548
Jering et al. Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Secondary Analysis of the HELIOS-B Randomized Clinical Trial
Cardiology · JAMA Cardiol · 2026-10-01

Post hoc analysis of HELIOS-B in 644 patients with ATTR cardiomyopathy: worse LA reservoir strain predicted death or cardiovascular events (HR 1.37 per 5% worsening), but LA volume did not. Vutrisiran vs placebo lessened LA strain decline at 30 months (+1.2%).

Secondary analysisn = 644
Jering et al. Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial
Cardiology · Lancet · 2026-09-30

In 2749 adults with type 2 diabetes and high cardiovascular risk, oral orforglipron was non-inferior to insulin glargine for MACE-4 over 2 years (4.2% vs 5.0%; HR 0.84, 95% CI 0.59-1.20). GI adverse events were more common (62% vs 14%).

RCTn = 2,749
Klein et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial
Cardiology · J Am Coll Cardiol · 2026-09-29

The 2026 AHA/ACC multisociety guideline on perioperative cardiovascular evaluation and management of adults having noncardiac surgery replaces the 2014 guideline, updating recommendations with new evidence on drug therapy, perioperative monitoring and devices.

Guideline
Thompson et al. 2026 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Cardiology · BMJ · 2026-09-23

In an IPD network meta-regression of 35 trials (8679 adults with major depression), escitalopram (+8.7 ms) and amitriptyline (+5.3 ms) were associated with longer QTc vs placebo over 8 weeks. Aggregate data from 139 trials showed no link between antidepressants and early MACE.

Meta-analysisn = 8,679
Ostinelli et al. QTc changes and early major adverse cardiovascular events associated with antidepressant treatment for major depressive disorder in adults: individual participant data network meta-regression of double blind randomised trials

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.